Liangliang Chen
79 Qingchun Road
Hangzhou, 310003, China
Hangzhou, 310003, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Epidemiological characteristics and factors associated with chronic kidney disease-associated pruritus in the Chinese adult dialysis population: a multicenter, cross-sectional study.
Journal: Renal failure
Published: August 28, 2026
Cyclophosphamide Plus Rituximab Versus Cyclophosphamide in Antineutrophil Cytoplasmic Antibody-associated Vasculitis With Kidney Involvement: A Retrospective Cohort Study in China.
Journal: Kidney medicine
Published: January 08, 2026
The Effectiveness of Three Steps Training in Clinical Reasoning for Clerkship Medical Students, a Pilot Trial in Nephrology Department.
Journal: Medical science educator
Published: December 17, 2025
ZFP36 and CEBPA are macrophage-associated prognostic biomarkers linked to glomerular endothelial inflammation in ANCA-associated glomerulonephritis.
Journal: Experimental cell research
Published: December 06, 2025
Estimated Glomerular Filtration Rate Slope Predicts Survival and Renal Outcomes in Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis: Development and Validation of a Pathogen-Free Model.
Journal: Kidney diseases (Basel, Switzerland)
Published: September 21, 2025
Comparison and prognostic analysis of focal segmental glomerulosclerosis patients with or without nephrotic syndrome at onset.
Journal: BMC nephrology
Published: April 29, 2025
Curcumin-loaded polydopamine nanoparticles-based antioxidant scaffold promote spinal cord repair though dural-regulation of macrophage polarization.
Journal: Materials today. Bio
Published: February 20, 2025
Systemic lupus erythematosus therapies: a decade of progress and prospects in clinical trials.
Journal: Journal of translational medicine
Published: January 31, 2025
Effects of Packet Loss on Neural Decoding Effectiveness in Wireless Transmission.
Journal: Brain sciences
Published: January 07, 2025
Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab.
Journal: American journal of nephrology
Published: August 14, 2024
Obinutuzumab in Refractory Membranous Nephropathy: A Case Series.
Journal: Kidney medicine
Published: August 05, 2024
Last Updated: 09/26/2026